

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Medical & HealthCare Group Limited

(Incorporated in Bermuda with limited liability)

(Stock Code: 383)

POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders of the Company and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the five months ended 30 November 2016 and information currently available, it is expected to record a profit attributable to shareholders of the Company for the six months ended 31 December 2016 as compared with a loss in 2015, mainly due to the realized and mark-to-market unrealized gains from investments held for trading and derivative financial instruments. The financial markets partially recovering from the initial adverse impact of Brexit and the results of the US presidential election although uncertainties still remain about the outlook for global economic growth and geopolitical tension.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

This announcement is made by China Medical & HealthCare Group Limited (the “Company”, together with its subsidiaries, collectively the “Group”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (the “SFO”).

The board of the directors of the Company (the “Board”) wishes to inform the shareholders of the Company and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the five months ended 30 November 2016 and information currently available, it is expected to record a profit attributable to shareholders of the Company for the six months ended 31 December 2016 as compared with a loss in 2015, mainly due to the realized and mark-to-market unrealized gains from investments held for trading and derivative financial instruments. The financial markets partially recovering from the initial adverse impact of Brexit and the results of the US presidential election although uncertainties still remain about the outlook for global economic growth and geopolitical tension.

This positive profit alert announcement is only based on the preliminary review on the relevant unaudited consolidated management accounts of the Group for the five months ended 30 November 2016 and the information currently available, which have not been confirmed or reviewed by the Company's auditor. The Company is in the process of finalizing the interim results for the six months ended 31 December 2016 and shareholders of the Company and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended 31 December 2016, which is expected to be released before the end of February 2017.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
China Medical & HealthCare Group Limited
Dr. Lim Cheok Peng
Chairman

Hong Kong, 11 January 2017

As at the date of this announcement, the Board comprises: -

Executive Directors

Ms. Chong Sok Un (Deputy Chairman), Dr. Jonathan Weiyan Seah (Chief Executive Officer), Dato' Wong Peng Chong and Mr. Kong Muk Yin

Non-Executive Directors

Dr. Lim Cheok Peng (Chairman) and Mr. Liao Feng

Independent Non-Executive Directors

Mr. Lau Siu Ki, Mr. Zhang Jian and Dr. Xia Xiaoning